Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of JP-1366-based bismuth quadruple therapy for Helicobacter pylori eradication
CTR20261590Phase 3Active
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zastaprazan in Helicobacter pylori infection, sponsored by Livzon Pharmaceutical Group Inc.. Started May 2026; status: active.
02
Drugs
zastaprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on CTR20261590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261590.